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INTRODUCTION
Obesity is one of the major health challenges of the 21st
century (Phyllis et al., 2005; Alizadeh et al., 2013). Chil-
dren and adolescents with obesity are at a high risk of de-
veloping obesity-related diseases such as cardio-vascular
diseases, arterial hypertension (AH), dyslipidemia, meta-
bolic syndrome (MS), type 2 diabetes mellitus (T2DM), dif-
ferent types of tumours, orthopedic problems, and serious
psychological and neurological problems, etc. (Phyllis et
al., 2005; Halpern et al., 2010; Alizadeh et al., 2013).
The number of adolescents being diagnosed with T2DM is
increasing in America, Europe, Japan and Australia (Phyllis
et al., 2005). Increase of T2DM among adolescents is attrib-
uted to spread of unhealthy habits, increasing obesity
among children and teenagers, and better diagnostics.
(Halpern et al., 2010). Unfortunately, no study on T2DM
has been done in Latvia in recent years.
Diabetes-related morbidity is caused by microvascular and
macrovascular complications, which lead to early disability
and premature death (Pinhas-Hamiel et al., 2007). Even at
the moment of diagnosing T2DM, patients can already have
serious comorbidities, such as arterial hypertension, dyslipi-
demia, fatty liver etc. (Rosenbloom et al., 2008).
Early detection of T2DM and impaired glucose tolerance
(IGT) in adolescents is essential, as early combined therapy
can reduce future complications. This group of patients
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The world has seen a rise of type 2 diabetes mellitus in children during the last 20 years. It is pro-
posed that this increase is due to unhealthy eating habits, increasing obesity, especially among
teenagers, and better diagnostics. The main risks associated with diabetes are microvascular and
macrovascular complications, which can lead to early disability and premature death. The aim of
our study was to identify children with type 2 diabetes mellitus or impaired glucose tolerance and
investigate associated comorbidities at the time of diagnosis in the Children’s Clinical University
Hospital in Latvia. A retrospective analysis was performed of all children with type 2 diabetes
mellitus or glucose tolerance impairment from 2002 till 2013, who were treated in Children’s En-
docrinology Centre. According to inclusion criteria, 57 patients were selected of whom 24 (42%)
had type 2 diabetes mellitus and 33 (58%) had impaired glucose tolerance. Body mass index was
analysed according to percentile and all patients were found to have excess weight. In children
with type 2 diabetes mellitus, all patients had body mass index over the 99th percentile. Arterial
hypertension was found in 66.7% and dyslipidemia in 54.2% type 2 diabetes mellitus patients.
From all type 2 diabetes mellitus patients, 71% (n = 17) were girls and they had statistically signif-
icantly higher total cholesterol (p = 0.02) and low-density lipoprotein (p = 0.003) levels. Con-
sidering, that girls with type 2 diabetes mellitus have high cardiovascular risk in adulthood, it is
very important not only to achieve normal glucose levels early, but also to treat comorbidities, to
reduce further microvascular and macrovascular complication risk.
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needs extensive lifestyle correction — balanced diet, ade-
quate physical activity, lifestyle modification to alter un-
healthy habits and weight reduction (Phyllis et al., 2005;
Halpern et al., 2010; Alizadeh et al., 2013).
The American Academy of Pediatrics and the American Di-
abetes Association recommend T2DM screening for adoles-
cents who are overweight and who have two of the follow-
ing risk factors: a first or second-degree relative with
diagnosed type 2 diabetes; those belonging to ethnic popu-
lations with increased risk (e.g., African–American, Ameri-
can Indians, Asian and Pacific Islander ethnicities); those
with one of the symptoms related to insulin resistance —
acanthosis nigricans, arterial hypertension, dyslipidemia or
polycystic ovary (PCO) syndrome. The screening com-
mences either at 10 years of age or at the onset of puberty
(if it is premature), and is repeated every two years. The
first examination when starting screening for T2DM in ado-
lescents is measurement of fasting glucose. However, the
more accurate, but also more cumbersome examination is
the oral glucose tolerance test (OGTT) (Phyllis et al., 2005).
Considering that there have not been any studies looking at
T2DM epidemiology in children, our study was aimed to
identify children groups with type 2 diabetes mellitus or im-
paired glucose tolerance and associated comorbidities at the
moment of establishing diagnosis. The study was conducted
at the Children’s Clinical University Hospital in Latvia.
MATERIALS AND METHODS
Samples, anthropometry and blood tests. A retrospective
analysis was performed of all children with type 2 diabetes
mellitus or glucose tolerance impairment, who were treated
in Children’s Endocrinology Centre at the Children’s Clini-
cal University Hospital Riga from 2002 till 2013. In total 57
patient cases with impaired glucose tolerance (IGT) or type
2 diabetes mellitus (T2DM) were analysed and they repre-
sented only 1.38% of all patients treated in the Children’s
Endocrinology centre during that period. All 57 patients had
been hospitalised to perform type 2 diabetes mellitus
screening using the oral glucose tolerance test (OGTT). Af-
ter a 12-h overnight fasting, the subjects underwent an
OGTT at 08.00 a.m. Glucose was given orally (1.75 g/kg
body weight, up to a maximum of 75 g glucose). Blood
samples were drawn after 30, 60, 90, and 120 min. Diagno-
sis of IGT was made if the blood glucose level after 2 hours
was  7.8–11.0 mmol/l. Diagnosis of T2DM was made if
fasting glucose was  7.0 mmol/l in venous plasma, or
two-hour glucose during OGTT was  11.1 mmol/l in ve-
nous plasma (Wiegand et al., 2004).
In our descriptive retrospective study, we analysed and
summarised patient weight, height, age and blood pressure
(BP) rates during hospitalisation. The body mass index
(BMI) was calculated using the formula weight (kg)/height
(m)2 and evaluated using percentile charts adjusted to age
and gender. Baseline test results were obtained for measure-
ment of fasting (venous) thyroid-stimulating hormone
(TSH), total cholesterol (TC), triglycerides (TG), high-den-
sity lipoprotein (HDL), low-density lipoprotein (LDL),
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), glucose and C-peptide.
Blood pressure measurements were assessed according to
percentile charts for the relevant age, height and gender. Ar-
terial hypertension was diagnosed if the systolic and/or dia-
stolic blood pressure in the > 95 percentile in three repeated
measurements (Dinesh et al., 2012).
Dyslipidemia was diagnosed using the criteria developed by
the National Institutes of Health Heart, Lung and Blood In-
stitute (NHLBI): TC  5.2 mmol/l, TG  1.5 mmol/l, LDL
 3.4 mmol/l, HDL < 1.00 mmol/l (Yoon, 2014).
The Ethics Committee of the Rîga Stradiòð University ap-
proved the study.
Statistical analysis. In our study we used nonparametric
statistics descriptive indicators — median, quartiles, inter-
quartile range. Groups were compared with the Mann–
Whitney test. A probability value of less than 0.05 was con-
sidered significant. Statistical analysis was performed using
IBM SPSS Statistics for Windows, version 22.0.
RESULTS
In total, there were 57 patients included in the study. There
were 24 (7 boys (29%) and 17 girls (71%)) diagnosed with
type 2 diabetes mellitus, while 33 patients (21 boy (63%)
and 12 girls (37%)) had impaired glucose tolerance. Median
age in the T2DM group was 15 (13.3–17.0 years), in im-
paired glucose tolerance group — 14 (12.0–16.0). There
was no statistically significant age difference between the
groups (p = 0.912).
All included children had elevated BMI. In the T2DM
group, all children had elevated BMI above the 99th percen-
tile and were deemed obese. In the impaired glucose toler-
ance group, there were four overweight children (BMI
above 85th percentile), while the others had above the 95th
percentile.
There was a statistically significant (p < 0.001) diastolic
blood pressure difference between the groups — in the
T2DM group median diastolic blood pressure was 85
mmHg (75–90 mmHg), while in the IGT group — 80
mmHg (72–90 mmHg). Laboratory parameters revealed a
statistically significantly (p = 0.011) lower HDL in the
T2DM group (Table 1).
Girls with T2DM had significantly higher total cholesterol
(median 5.2 mmol/l (4.5–5.5)) than girls in the IGT group
(median 4.1 mmol/l (3.3–4.9)) (p = 0.02). Also, LDL was
significantly higher in T2DM girls (p = 0.003), than in girls
in the IGT group (Table 2).
There was a statistically significant difference between the
groups (p = 0.035) in BMI of boys — in the T2DM group
median BMI in boys was 31.3 kg/m2 (30.8–40.4), while in
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the IGT group — 25.9 kg/m2 (18.9–35.2). There were no
statistically significant differences in other parameters be-
tween the groups in boys (Table 3).
At the time of diagnosis, arterial hypertension was found in
16 (66.7%) of T2DM patients and 18 (54.5%) patients with
IGT. There were no statistically significant differences
found between the groups concerning arterial hypertension
(p = 0.28).
At the time of diagnosis, 13 (54.2%) T2DM patients and
5 (15.2%) IGT patients had dyslipidemia, and this differ-
ence was statistically significant between the groups (p =
0.03).
DISCUSSION
Numerous studies and observations have been carried out
investigating excess weight, impaired glucose tolerance and
type 2 diabetes mellitus in children (Eyzaguirre et al., 2009;
Huang et al., 2009). There are many modifiable and
non-modifiable risk factors for childhood obesity. This is
important because prevention of childhood obesity reduces
the possibility of developing IGT and T2DM ( Maahs et al.,
2008; Huang et al., 2009).
Evidence shows that T2DM in children not only differs
from type 1 diabetes, but also from type 2 diabetes in
adults. It is characterised by a quick decline in the beta cell
secretory rate and earlier development of diabetes complica-
T a b l e 1
CHARACTERISTICS OF T2DM AND IGT GROUPS
Variables T2DM group n = 24 IGT group n = 33 p-value
median (interquartile range) median (interquartile range)
Age, years 15.0 (13.3–17.0) 14.0 (12.0–16.0) 0.912
Weight, kg 84.0 (67.0–101.0) 74.5 (56.7–107.3) 0.808
Height, m 1.7 (1.5–1.7) 1.7 (1.5–1.7) 0.141
BMI, kg/m2 31.2 (27.3–38.7) 28.6 (24.0–36.4) 0.058
Glucose, mmol/l 6.1 (5.3–6.4) 5.5 (5.1–6.0) 0.093
c-peptide, ng/ml 3.6 (2.5–5.1) 2.7 (1.5–4.2) 0.780
ALT, U/l 26.0 (18.0–66.0) 31.0 (15.1–49.0) 0.705
AST, U/l 21.5 (17.0–68.9) 28.0 (22.9–36.9) 0.209
TSH, mU/l 2.0 (1.5–3.1) 2.5 (1.6–3.9) 0.008
TC, mmol/l 5.2 (4.4–5.6) 4.3 (3.4–5.0) 0.654
HDL, mmol/l 1.1 (0.9–1.4) 1.2 (1.0–1.3) 0.011
LDL, mmol/l 3.2 (2.8–3.4) 2.6 (2.0–2.7) 0.083
TG, mmol/l 1.7 (1.2–2.5) 1.2 (0.8–1.8) 0.515
Systolic BP, mmHg 140.0 (127.5–146.0) 130.0 (121.5–145.0) 0.609
Diastolic BP, mmHg 85.0 (75.0–90.0) 80.0 (72.0–90.0) 0.001
T a b l e 2
ANTHROPOMETRIC AND LABORATORY VALUES IN GIRLS WITH T2DM AND IGT
Variables T2DM group n = 17 IGT group n = 12 p-value
median (interquartile range) median (interquartile range)
Age, years 15.0 (13.3–17.0) 14.0 (13.0–16.5) 0.444
Weight, kg 79.0 (65.5–98.8) 93.0 (70.6–107.0) 0.294
Height, m 1.7 (1.5–1.7) 1.7 (1.6–1.7) 0.512
BMI, kg/m2 30.5 (27.1–37.5) 34.5 (26.9–37.4) 0.680
Glucose, mmol/l 5.9 (5.1–7.1) 5.4 (5.3–6.0) 0.302
c-peptide, ng/ml 3.5 (2.2–5.1) 3.0 (2.2–3.9) 0.581
ALT, U/l 21.0 (16.5–104.7) 28.8 (14.0–51.1) 0.904
AST, U/l 21.5 (16.5–73.6) 23.9 (20.6–35.3) 0.927
TSH, mU/l 1.7 (1.4–3.1) 2.5 (1.6–3.1) 0.251
TC, mmol/l 5.2 (4.5–5.5) 4.1 (3.3–4.9) 0.02
HDL, mmol/l 1.1 (0.8–1.4) 1.3 (1.2–1.4) 0.211
LDL, mmol/l 3.1 (2.9–3.5) 2.0 (1.8–2.6) 0.003
TG, mmol/l 1.9 (1.2–2.1) 0.9 (0.6–1.9) 0.211
Systolic BP, mmHg 140.0 (120.0–145.0) 137.0 (120.0–145.0) 1
Diastolic BP, mmHg 80.0 (75.0–90.0) 90.0 (75.0–95.0) 0.721
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tions (Copeland et al., 2011).The following risk factors are
considered for T2DM in children — obesity, family history
of diabetes, female gender and low socioeconomic status.
(Copeland et al., 2011).
In our study at the time of hospitalisation all patients were
overweight, so IGT/T2DM screening was initiated. Most of
the patients with T2DM diagnosis were girls (71%, n = 17).
In our study we did not analyse other risk factors, such as
positive diabetes family history and socioeconomic status.
In young people T2DM is diagnosed more frequently dur-
ing the second decade of life and the average age of diagno-
sis is 13.5, coinciding with the physiological peak of insulin
resistance (Ball et al., 2006). In our study median age in pa-
tients with T2DM was 15, which means that diabetes
screening in children was performed early enough.
The type 2 diabetes diagnosed in adolescence is more fre-
quently associated with medical conditions other than type
1 diabetes (T1D) (Godoy-Matos et al., 2005; Eppens et al.,
2006; Kershnar et al., 2006; Pinhas-Hamiel et al., 2007;
Önal et al., 2014). Microvascular complications (retino-
pathy), nephropathy, peripheral neuropathy and macro-
vascular complications affect the quality of life as well as
long term morbidity and mortality. Many studies have
shown that the risk of arterial hypertension and dys-
lipidemia is much higher in patients with T2DM than in pa-
tients with T1DM (Godoy-Matos et al., 2005). A multi-
centre study in USA showed that arterial hypertension was
found in 10–32% of patients with T2DM and was eight
times more likely than in patients with T1DM in the same
age group. Isolated or combined dyslipidemia was found in
24–44% of cases (Kershnar et al., 2006). In our study
dyslipidemia was found in 54.2% and arterial hypertension
in 66.7% of children at T2DM diagnosis.
This finding is very alarming, because children with T2DM
and other cardiovascular risk factors, such as arterial hyper-
tension, have drastically increased cardiovascular and pre-
mature death risk. Considering that average cardiovascular
disease mortality in Latvia is higher in women (6%) than
men, more attention has to be directed to girls with excess
weight (Ðtâle et al., 2012). Our study showed significantly
higher total cholesterol and low-density lipoprotein levels in
girls with T2DM, which is associated with increased cardio-
vascular disease risk. The treatment should not only focus
on normalising glucose levels, but also on controlling
comorbidities.
The basic treatment goals for children and adolescents with
T2DM are: psychologic and family support therapy, weight
reduction; lifestyle corrections — balanced diet and in-
creased physical activity. The next step is achieving normal
glucose levels and controlling comorbidities, including hy-
pertension, dyslipidemia and hepatic steatosis (Godoy-
Matos et al., 2005; Phyllis et al., 2005; Maahs et al., 2008;
Huang et al., 2009). This strategy would be especially im-
portant to children with impaired glucose tolerance.
Adult studies have shown, that lifestyle corrections are
more effective than pharmacotherapy in preventing T2DM
in patients with impaired glucose tolerance. Pharmaco-
therapy is very limited in children with T2DM, and the only
approved medication is metformin. Even after the pharma-
cotherapy is initiated, lifestyle corrections have to be con-
tinued to reduce the possibility of complications (Rodbard
et al., 2007).
CONCLUSIONS
This retrospective study showed that at the moment of diag-
nosis of T2DM, 54.2% children had dyslipidemia and
66.7% had arterial hypertension. Most of the T2DM pa-
T a b l e 3
ANTHROPOMETRIC AND LABORATORY VALUES IN BOYS WITH T2DM AND IGT
Variables T2DM group n = 7 IGT group n = 21 p-value
median (interquartile range) median (interquartile range)
Age, years 15.0 (13.0–17.0) 13.0 (10.0–16.0) 0.228
Weight, kg 90.0 (81.0–120.0) 65.0 (54.0–108.0) 0.107
Height, m 1.7 (1.6–1.8) 1.7 (1.4–1.7) 0.306
BMI, kg/m2 31.3 (30.8–40.4) 25.9 (18.9–35.2) 0.035
Glucose, mmol/l 6.1 (5.3–6.4) 5.5 (4.9–6.0) 0.155
c-peptide, ng/ml 3.6 (3.0–5.2) 2.6 (1.3–4.4) 0.139
ALT, U/l 34.0 (19.0–37.8) 34.2 (15.7–49.0) 1
AST, U/l 21.5 (17.5–65.7) 31.8 (24.9–38.8) 0.397
TSH, mU/l 2.9 (1.8–3.8) 2.6 (1.8–3.9) 0.866
TC, mmol/l 5.2 (3.9–5.7) 4.3 (3.4–5.1) 0.187
HDL, mmol/l 1.2 (1.0–1.3) 1.1 (0.9–1.3) 0.494
LDL, mmol/l 3.3 (1.9–3.4) 2.6 (2.0–3.1) 0.407
TG, mmol/l 1.6 (1.3–2.5) 1.3 (1.0–1.7) 0.447
Systolic BP, mmHg 140.0 (135–149.0) 130.0 (121.8–147.5) 0.220
Diastolic BP, mmHg 90.0 (75.0–90.0) 80.0 (69.8–90.0) 0.423
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tients were girls 71%. Considering, that girls with type 2
diabetes mellitus have high cardiovascular risk in adult-
hood, it is very important not only to achieve normal glu-
cose levels early, but also to treat comorbidities, to reduce
further microvascular and macrovascular complication risk.
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2. TIPA CUKURA DIABÇTS, GLIKOZES TOLERANCES TRAUCÇJUMI BÇRNIEM UN ASOCIÇTÂS BLAKUS SASLIMÐANAS
BÇRNU KLÎNISKÂS UNIVERSITÂTES SLIMNÎCÂ LATVIJÂ, 2002–2013
Pçdçjo 20 gadu laikâ pasaulç strauji pieaug saslimstîba ar 2. tipa cukura diabçtu bçrniem. Saslimstîbas pieaugums tiek skaidrots ar
neveselîgu paradumu izplatîbu, strauju aptaukoðanâs izplatîbu bçrniem, it îpaði pusaudþiem, kâ arî ar diagnostikas uzlaboðanos. Galvenâ
saslimstîbas ar cukura diabçtu problçma ir mikrovaskulâru un makrovaskulâru komplikâciju attîstîba, kas ir par iemeslu agrînai invaliditâtei
un priekðlaicîgai nâvei. Pçtîjuma mçríis bija apzinât bçrnu grupu ar 2. tipa cukura diabçtu un glikozes tolerances traucçjumiem un pçtît
asociçtâs blakus saslimðanas diagnozes noteikðanas brîdî Bçrnu klîniskâs universitâtes slimnîcâ Latvijâ. No visâm stacionâra pacientu
slimîbas vçsturçm, kas ârstçjuðies laikâ posmâ no 2002. lîdz 2013. gadam Bçrnu endokrinoloìijas centrâ, tika retrospektîvi atlasîtas
pacientu slimîbas vçstures ar glikozes tolerances traucçjumu vai 2. tipa cukura diabçta diagnozi. Iekïauðanas kritçrijiem atbilda 57 pacientu
vçstures. 24 (42%) pacientiem bija diagnosticçts 2. tipa cukura diabçts, bet 33 (58%) pacientiem glikozes tolerances traucçjumi. Visiem
pçtîjuma bçrniem, retrospektîvi izvçrtçjot íermeòa masas indeksu atbilstoði procentîïu lîknçm pçc vecuma un dzimuma, bija konstatçts
liekais svars. 2. tipa cukura diabçta bçrnu grupâ bija konstatçta aptaukoðanâs, jo íermeòa masas indekss bija virs 99. procentîles. Jau 2. tipa
cukura diabçta diagnosticçðanas brîdî 54.2% bçrnu bija konstatçta dislipidçmija un 66.7% — arteriâlâ hipertensija. 2. tipa cukura diabçts
71% (n = 17) gadîjumu bija diagnosticçts meitençm. Statistiski nozîmîgi meitençm ar 2. tipa cukura diabçtu bija augstâks kopçjais
holesterîna lîmenis (p = 0,02) un zema blîvuma lipoproteîna lîmenis (p = 0,003). Òemot vçrâ, ka meitençm ar 2. tipa cukura diabçtu ir
augsts risks sirds un asinsvadu slimîbâm pieauguðo vecumâ, nepiecieðams agrîni pievçrst uzmanîbu ne tikai glikozes lîmeòa normalizâcijai,
bet arî blakusslimîbu kontrolei, lai mazinâtu turpmâkas mikrovaskulâro un makrovaskulâro komplikâciju attîstîbas risku.
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